K-Cast

K-Cast interview with C. Brooke Adams, Pharm.D., BCOP, of the Orlando Health Cancer Institute about bispecific antibody therapies for multiple myeloma.

This Managed Healthcare Executive K-Cast Series “Evolving Treatment Paradigms in Hemophilia,” led by Dr. Annette Von Drygalski, explores the transformation of hemophilia care from traditional factor replacement to advanced nonfactor therapies, examining their mechanisms, clinical data, and impact on patients, clinicians, and payers.

An expert discusses the escalating challenges of cardiovascular and kidney diseases in the U.S., underscoring the vital roles of early detection, holistic and multidisciplinary care, lifestyle modifications, and integrated healthcare strategies to prevent disease progression and improve overall patient health outcomes.

Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, discusses how various nonstatin LDL-lowering therapies including ezetimibe, bempedoic acid and PCSK9 inhibitors can be used in combination to achieve aggressive cholesterol targets for cardiovascular risk reduction, particularly in patients with statin intolerance or those requiring intensive secondary prevention.

An expert discusses the integration of bispecific antibodies into relapsed/refractory multiple myeloma care pathways, highlighting the importance of stakeholder alignment, care coordination, and patient onboarding, while emphasizing strategies for education and shared decision-making to support informed treatment choices.

A panelist reviews current evidence-based strategies for managing transplant-ineligible multiple myeloma, focusing on frontline anti-CD38–based regimens supported by trials like IMROZ and CEPHEUS, compares available therapies in terms of efficacy, safety, and administration route—including the quality-of-life benefits of subcutaneous options—and evaluates real-world data to guide treatment selection, value-based care, and equitable access for non-transplant candidates.

Marwan Fakih, M.D., discusses how squamous cell anal carcinoma has doubled in incidence over 30 years, with human papillomavirus (HPV) as the primary risk factor amplified by immunosuppression, leading to the evolution from historical cisplatin-based treatments to carboplatin/paclitaxel and now to the new standard of care combining retifanlimab with chemotherapy based on the landmark POD1UM-303 trial, which demonstrated significant improvements in progression-free survival (9.3 vs 7.4 months), response rates and overall survival trends, while emphasizing the need for widespread dissemination of this level-one evidence and exploring future therapeutic innovations including combination immunotherapies, cellular therapies targeting HPV antigens and antibody-drug conjugates.

Kimber Simmons, MD, MS, discusses how type 1 diabetes is a progressive autoimmune disease requiring early identification through autoantibody screening and C-peptide monitoring, with management approaches evolving from reactive insulin replacement toward proactive immunomodulation and beta cell preservation strategies that can alter disease trajectory and improve outcomes.

Matthew Zirwas, MD, discusses atopic dermatitis, its symptoms and impact on quality of life, the current treatment landscape with barriers to access of topical therapies, and new and emerging therapies that may transform treatment approaches and clinical practice.

Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, shares comprehensive insights on institutional approaches to biosimilar adoption, covering evaluation criteria, operational challenges, stakeholder management, safety protocols, payer dynamics, and future strategic considerations for successful implementation across health care settings.

Anna-Maria Hoffmann-Vold, MD, PhD, discusses how early diagnosis and intervention in progressive pulmonary fibrosis (PPF) can improve patient outcomes, address unmet treatment needs, and optimize healthcare resource utilization.

In this discussion on vitiligo, Seemal Desai, M.D., FAAD, explores disease mechanisms, diagnostic approaches, emerging therapies, treatment optimization, managed care considerations and psychosocial support strategies, emphasizing personalized care while addressing access barriers and the integration of digital health technologies to improve patient outcomes.

Sean M. Oser, MD, MPH, discusses strategies for optimal diabetes management.

Arwen Podesta, MD, explores prescription digital therapeutics as a solution for addressing unmet needs in patients with mental health conditions.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, provides clinical insights on the treatment of myelofibrosis, highlighting currently available therapies, ongoing research, and cost concerns.

Insights surrounding intravenous and subcutaneous biologic therapy utilization are presented by medical experts.

Paul W. Noble, MD, discusses key updates in treatment for idiopathic pulmonary fibrosis.

Lawrence Eichenfield, MD, provides insights on the treatment of atopic dermatitis, highlighting its impact on patients, the evolving therapeutic landscape, and areas of unmet need.

Selina McGee, OD, FAAO, investigates the clinical implications of Demodex blepharitis and its impact on patient well-being, considering the wide range of symptoms and potential secondary complications, while also reviewing the latest FDA-approved therapy.

Mahsa Salsabili, PharmD, PhD, explores the current landscape and potential optimization strategies for prescription digital therapeutics by payers and providers in managing various conditions, including diabetes, chronic pain, addiction, and behavioral health disorders.

Joseph Chervenak, MD, MBA, analyzes psychosocial, socioeconomic, and clinician-specific challenges associated with reproductive medicine treatment.

Christopher Starr, MD, FACS, provides an overview of current challenges and key treatment options for Demodex blepharitis.

An expert discusses how payers and providers are embracing biosimilars and unbranded biologics as they enter the marketplace.

James Lewis, PharmD, FIDSA, discusses vaccine hesitancy, vaccination status, and accessibility to vaccines across various patient populations.

Medical experts highlight key factors impacting the treatment landscape of spinal muscular atrophy (SMA).

Douglas K Devries, OD, discusses an overview on treatment pathways and burden of disease associated with Demodex blepharitis.

Dr David Rosmarin, MD, explores the treatment landscape and clinical burden associated with vitiligo.

A discussion series reviewing the differences between unbranded biologics and biosimilars and an overview of payer and provider considerations for decision-making.